NICE restricts semaglutide to BMI 35 kg/m, shrinking the eligible population by 60% relative to FDA criteria [3]National Institute for Health and Care Excellence, Semaglutide Guidance, nice.org.uk
How are GLP-1 receptor agonists administered
Lilly ha anunciado recientemente resultados detallados de dos ensayos clnicos de fase avanzada que demuestran que las personas con obesidad mantuvieron su prdida de peso a largo plazo tanto con orforglipron como con las dosis bajas de tirzepatida , despus de cambiar de una terapia inyectable con incretinas con la mxima dosis
Eksperimentalnaia i Klinicheskaia Farmakologiia, 75 (6), 8-13
Abstract Background There is currently a large arsenal of antidiabetic drugs available to treat type 2 diabetes (T2D)
*Based on self-reported data from approximately 1900 Bioverse customers on a personalized treatment plan including compounded GLP-1 injections, along with a reduced calorie diet and exercise